New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
08:09 EDTISIS
theflyonthewall.com: Isis Pharmaceuticals mipomersen benefits outweighs risks, says Needham
After the results of the Phase 3 trial of Isis' mipomersen were presented, Needham believes that the side effects of the drug are manageable and the firm expects the drug to be approved in 1H11. Needham reiterates a Buy rating on the stock. :theflyonthewall.com



News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2010
14:18 EDTISIS
theflyonthewall.com: Isis Pharmaceuticals April puts active on elevated volatility into data
Isis Pharmaceuticals is recently up 55c to $11.26. Data is expected in Q1 for Isis Pharmaceuticals mipomersen phase 3 trial study in patients with homozygous familial hypercholesterolemia. ISIS April 10 puts have traded 42 times on transaction volume of 5,060 contracts, above its open interest of 2,286 contracts. February option implied volatility is at 52, March is at 53, April is at 63, and July is at 58; above its 26-week average of 52 according to Track Data, suggesting larger price movement into data. :theflyonthewall.com
07:12 EDTISIS
theflyonthewall.com: Isis Pharmaceuticals shares could recover to mid-teens, says Citigroup

Subscribe for More Information
:theflyonthewall.com